Kauris-CPS 1 Injection is a sterile, injectable antibiotic formulation combining Cefoperazone 500 mg, a third-generation cephalosporin, with Sulbactam 500 mg, a beta-lactamase inhibitor. This synergistic combination enhances the antibacterial spectrum by inhibiting beta-lactamase enzymes produced by resistant bacteria, thereby restoring and extending the efficacy of Cefoperazone against a broad range of aerobic and anaerobic pathogens. Kauris-CPS 1 Injection is indicated for the treatment of serious infections caused by susceptible strains, including lower respiratory tract infections, urinary tract infections, intra-abdominal infections, skin and soft tissue infections, septicemia, and gynecological infections. The drug exhibits potent activity against gram-positive and gram-negative bacteria, including beta-lactamase producing strains of Escherichia coli, Klebsiella, Proteus, Pseudomonas aeruginosa, and Staphylococcus aureus. Administration is typically via intravenous or intramuscular injection as per the severity and site of infection, with dosage adjusted according to renal function and clinical response. Adverse effects are generally mild and may include gastrointestinal disturbances, hypersensitivity reactions, and transient hematological changes. Kauris-CPS 1 Injection should be used under medical supervision with appropriate microbiological monitoring to ensure optimal therapeutic outcomes and minimize resistance development.